Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JR-141 in Mucopolysaccharidosis Type II
NCT03128593Phase 2Completed
- Sponsor
- JCR Pharmaceuticals
- Start
- Mar 2017
- Primary completion
- Oct 2017
- Modality
- Replacement Enzymes, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of pabinafusp alfa in mucopolysaccharidosis type II, sponsored by JCR Pharmaceuticals. Started Mar 2017; status: completed.
02
Drugs
pabinafusp alfa
03
Conditions
mucopolysaccharidosis type II
Beyond the preview
Go deeper on NCT03128593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03128593.